Aclarion, Inc. Files 8-K with Corporate Updates
Ticker: ACONW · Form: 8-K · Filed: Jun 18, 2024 · CIK: 1635077
| Field | Detail |
|---|---|
| Company | Aclarion, INC. (ACONW) |
| Form Type | 8-K |
| Filed Date | Jun 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, financials
Related Tickers: ACON
TL;DR
ACON filed an 8-K on 6/18 for 6/12 events - corporate changes & financials filed.
AI Summary
Aclarion, Inc. filed an 8-K on June 18, 2024, reporting events that occurred on June 12, 2024. The filing indicates amendments to its Articles of Incorporation or Bylaws and includes financial statements and exhibits. The company, formerly known as Nocimed, Inc., is incorporated in Delaware and has its principal business address in Broomfield, Colorado.
Why It Matters
This 8-K filing signals potential changes in Aclarion's corporate structure or governance, which could impact its operational framework and investor relations.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain any immediate negative financial or operational news.
Key Players & Entities
- Aclarion, Inc. (company) — Registrant
- Nocimed, Inc. (company) — Former company name
- June 18, 2024 (date) — Date of Report
- June 12, 2024 (date) — Date of earliest event reported
- 8181 Arista Place, Suite 100 (location) — Business Address
FAQ
What specific amendments were made to Aclarion, Inc.'s Articles of Incorporation or Bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the provided text excerpt. Further review of the exhibits would be necessary.
What is the significance of filing financial statements and exhibits with this 8-K?
Filing financial statements and exhibits alongside the 8-K provides investors and the SEC with updated financial information and supporting documentation for the reported events.
When did Aclarion, Inc. change its name from Nocimed, Inc.?
The filing states the date of the name change was February 26, 2015.
What is Aclarion, Inc.'s Standard Industrial Classification (SIC) code?
Aclarion, Inc.'s SIC code is 8071, which corresponds to Medical Laboratories.
Where is Aclarion, Inc. incorporated and what is its IRS Employer Identification Number?
Aclarion, Inc. is incorporated in Delaware and its IRS Employer Identification Number is 47-3324725.
Filing Stats: 626 words · 3 min read · ~2 pages · Grade level 13.3 · Accepted 2024-06-18 16:01:21
Filing Documents
- acon_8k.htm (8-K) — 33KB
- acon_ex0301.htm (EX-3.1) — 5KB
- 0001683168-24-004321.txt ( ) — 255KB
- acon-20240612.xsd (EX-101.SCH) — 4KB
- acon-20240612_def.xml (EX-101.DEF) — 26KB
- acon-20240612_lab.xml (EX-101.LAB) — 36KB
- acon-20240612_pre.xml (EX-101.PRE) — 25KB
- acon_8k_htm.xml (XML) — 6KB
03. Amendments
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On June 12, 2024, the Board of Directors of Aclarion, Inc. (the "Company") adopted an amendment (the "Amendment") to the Company's bylaws that reduced the quorum required for the transaction of business at stockholder meetings from (i) the holders of a majority of the voting power of the outstanding shares of stock entitled to vote, to (ii) the holders of one-third of the voting power of the outstanding shares of stock entitled to vote. The Company has encountered difficulties reaching a quorum in the past due to the size and dispersed nature of the Company's stockholder base and the decision of many brokerage firms to eliminate discretionary voting even for "routine matters." Reducing the quorum requirement reduces the risk of failing to achieve the required quorum for any stockholder meetings, which failure would require the Company to adjourn such meetings and therefore cause the Company to incur additional costs, such as additional meeting host costs and proxy solicitation costs, and suffer other potential disruptions to its business and distraction for management. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 3.1 Amendment to Bylaws dated June 12, 2024 104 Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ACLARION, INC. June 18, 2024 /s/ John Lorbiecki Name: John Lorbiecki Title: Chief Financial Officer 3